Summit Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Summit Therapeutics Inc. (SMMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.92 million shares for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2023-11-07
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-09-30 was 2.17M shares, a 31.90% decline year-over-year.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-06-30 was 830.00K shares, a 85.66% decline year-over-year.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-03-31 was 918.95K shares, a 173.19% increase year-over-year.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was 521.17K shares, a 76.66% decline year-over-year.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 9.84M shares, a 25.82% decline from fiscal 2021.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 13.26M shares, a 323.00% increase from fiscal 2020.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 3.14M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 11 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|---|---|
| 2023-09-30 | 2.17M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 3.00M shares derived: sum of 2 quarters · filed 2023-11-07 | 3.92M shares 10-Q · filed 2023-11-07 | 4.44M shares derived: sum of 4 quarters · filed 2023-11-07 | |||
| 2023-06-30 | 830.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 1.75M shares 10-Q · filed 2023-08-09 | 2.27M shares derived: sum of 3 quarters · filed 2023-08-09 | 5.46M shares derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2023-03-31 | 918.95K shares 10-Q · filed 2023-05-11 | 1.44M shares derived: sum of 2 quarters · filed 2023-05-11 | 4.63M shares derived: sum of 3 quarters · filed 2023-05-11 | 10.42M shares derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2022-12-31 | 521.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 3.71M shares derived: sum of 2 quarters · filed 2023-03-09 | 9.50M shares derived: sum of 3 quarters · filed 2023-03-09 | 9.84M shares 10-K · filed 2023-03-09 | |||
| 2022-09-30 | 3.19M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 8.98M shares derived: sum of 2 quarters · filed 2022-11-09 | 9.32M shares 10-Q · filed 2022-11-09 | 11.55M shares derived: sum of 4 quarters · filed 2022-12-21 | |||
| 2022-06-30 | 5.79M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 6.13M shares 10-Q · filed 2022-08-11 | 8.36M shares derived: sum of 3 quarters · filed 2022-12-21 | 16.74M shares derived: sum of 4 quarters · filed 2022-12-21 | |||
| 2022-03-31 | 336.38K shares 10-Q · filed 2022-05-11 | 2.57M shares derived: sum of 2 quarters · filed 2022-12-21 | 10.95M shares derived: sum of 3 quarters · filed 2022-12-21 | 11.40M shares derived: sum of 4 quarters · filed 2022-12-21 | |||
| 2021-12-31 | 2.23M shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | 10.62M shares derived: sum of 2 quarters · filed 2022-12-21 | 11.07M shares derived: sum of 3 quarters · filed 2022-12-21 | 13.26M shares 10-K/A · filed 2022-12-21 | |||
| 2021-09-30 | 9.25M shares 10-Q · filed 2021-11-15 | 8.38M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 8.83M shares derived: sum of 2 quarters · filed 2021-11-15 | 11.03M shares 10-Q · filed 2021-11-15 | 8.09M shares derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2021-09-24 | 9.25M shares 10-K · filed 2023-03-09 | ||||||
| 2021-06-30 | 450.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 2.65M shares 10-Q · filed 2021-08-12 | -289.00K shares derived: sum of 3 quarters · filed 2021-08-12 | 1.93M shares derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2021-03-31 | 2.20M shares 10-Q · filed 2021-05-17 | -739.00K shares derived: sum of 2 quarters · filed 2021-05-17 | 1.48M shares derived: sum of 3 quarters · filed 2021-05-17 | ||||
| 2020-12-31 | -2.94M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -712.01K shares derived: sum of 2 quarters · filed 2021-03-31 | 3.14M shares 10-K · filed 2021-03-31 | ||||
| 2020-09-30 | 2.22M shares derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | 6.07M shares 10-Q · filed 2020-11-16 | |||||
| 2020-06-30 | 3.85M shares 8-K · filed 2020-09-29 | ||||||
| 2019-12-31 | 3.05M shares 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |